Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). Investor presentation furnished August 10, 2026 for institutional investor and analyst meetings.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished August 10, 2026 for institutional investor and analyst meetings
- Exhibit 99.2 contains the presentation, potentially updating investors on strategy, pipeline and business outlook
- Presentation availability on Aquestive’s investor website enables broader market access to management materials
Item 8.01 · Other Events
- Anaphylm human factors and pharmacokinetic study results announced
- Results support planned FDA New Drug Application resubmission for Type 1 allergic reactions, including anaphylaxis
- Regulatory progress could advance Anaphylm toward potential U.S. approval and commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.